ArticleDiscover oncology2025
Prognostic value of anoikis- and epithelial-mesenchymal transition-related genes and development of a prognostic risk model in thyroid cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thyroid cancer (TC) is a common endocrine malignancy, and the processes of anoikis resistance and epithelial–mesenchymal transition (EMT) are crucial in tumor metastasis. In this study, transcriptomic data from TC patients were obtained from The Cancer Genome Atlas (TCGA), and differential gene expression was analyzed using the Limma package. A total of 193 anoikis- and EMT-related genes were identified, and their overlap with differentially expressed genes (DEGs) was examined. Using VennDiagram, five hub genes (CARD10, DAPK1, FN1, S100A4, and SALL4) were selected for further analysis. These genes were incorporated into a prognostic risk model, developed through univariate Cox, LASSO, and multivariate regression analyses. The model showed strong predictive power, with area under the curve (AUC) values over 0.7 for 1-, 3-, and 5-year survival predictions. Immune cell infiltration analysis revealed significant differences between risk groups, with correlations to the EMT score. Furthermore, the expression of the hub genes was validated in TC tissues and cell lines, showing that four of the hub genes (excluding SALL4) were significantly associated with overall survival. This prognostic model offers valuable insights into the tumor immune microenvironment and identifies potential therapeutic targets for TC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.